Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 6.4% – Should You Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s share price was down 6.4% during mid-day trading on Wednesday . The company traded as low as GBX 0.95 ($0.01) and last traded at GBX 0.96 ($0.01). Approximately 6,211,438 shares traded hands during mid-day trading, a decline of 38% from the average daily volume of 10,021,008 shares. The stock had previously closed at GBX 1.03 ($0.01).

Hemogenyx Pharmaceuticals Stock Performance

The company has a market capitalization of £12.84 million, a P/E ratio of -95.00 and a beta of 3.14. The company has a current ratio of 4.38, a quick ratio of 6.72 and a debt-to-equity ratio of 92.09. The company’s fifty day moving average is GBX 1.35 and its 200 day moving average is GBX 1.36.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.